[ad_1]

Centene will pay $33 million to settle allegations that its now-defunct pharmacy benefit manager overcharged the Washington state Medicaid program for drugs.

The nation’s largest Medicaid insurer will pay $18.9 million to the Evergreen State and $13 million to the federal government to put an end to allegations of fraud by its former PBM, Washington Attorney General Bob Ferguson (D) announced Wednesday. Centene has settled with 11 states over accusations its pharmacy benefits arm, Envolve, inflated charges, according to a news release. The attorney general’s office declined to comment on whether it was investigating other PBMs over similar allegations.

Centene has publicly disclosed $312 million in no-fault agreements with eight states: Arkansas, Illinois, Kansas, New Hampshire, Mississippi, New Mexico, Ohio and Washington. Centene has also inked settlement deals with Louisiana, Nebraska and Nevada, a spokesperson for Ferguson’s office wrote in an email. California regulators are investigating Centene over similar fraud claims.

Attorneys general in these states did not immediately respond to interview requests about any agreements with Centene. Centene did not immediately respond to an interview request on additional settlements

Centene reserved $1.25 billion to settle PBM fraud allegations. The company exited the pharmacy business in July when it sold Magellan Rx and PANTHERx Rare in separate transactions collectively valued at $2.8 billion. By the end of the year, the insurer plans to finalize a contract with an outside PBM to manage its $40 billion in annual pharmaceutical spending.

[ad_2]

Source link

Leave a Reply

Explore More

Pear Therapeutics files Chapter 11, lays off 170 employees

[ad_1] Pear Therapeutics filed for Chapter 11 bankruptcy protection Friday and said it has eliminated most of its workforce. The filing, in bankruptcy court in Delaware, comes just three weeks

Insurtech CEOs paid much more than legacy insurer leaders

[ad_1] Mikan saw the second-highest growth in total compensation among health insurer chiefs. Oscar Health CEO Mario Schlosser got the largest increase, with stock awards issued last August driving his

U.S. data reveals racial gaps in monkeypox vaccinations

[ad_1] The Biden administration said Friday there’s enough monkeypox vaccine available now but health officials say the shots aren’t getting to some of the people who need the protection the